|
Active substance |
adalimumab |
|
Holder |
AbbVie SA |
|
Status |
closed |
|
Indication |
moderately to severely active Ulcerative Colitis in paediatric patients of 2 to 5 years old |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
08/12/2022 |
Humira®
Last updated on 13/09/2024